Introduction
============

*Candida*spp. is the third most common reason for sepsis in the ICU, not differentiating our results from the classic pattern of ICU-acquired infection. Prevention of sepsis development and identification of potentially modifiable risk factors are important goals in intensive care patents. Preemptive treatment of *Candida*sepsis accepted by some authors is defined as an early antifungal treatment given to patients with evidence of substantial colonization in the presence of multiple risk factors for *Candida*infection prior to establishing the diagnosis by cultures. Our aim was to form a focused group of patients with significant risk for *Candida*sepsis; to prove the feasibility and efficacy of our preemptive scheme for antimycotic treatment in order to reduce the risk of development of proved *Candida*sepsis.

Methods
=======

During a 2-year period (2005--2006), a study was performed in a 17-bed general ICU, divided into two phases: a case--control retrospective study in which controls comprising a representative subpopulation with severe bacterial sepsis were compared with cases (patients with *Candida*sepsis) with respect to multiple demographic and clinical factors in a univariate analysis; and a prospective phase creating a preemptive scheme based on results from the retrospective part followed by progressively implementing it among targeted patients.

Results
=======

Identified were 28 cases with *Candida*sepsis and 50 controls with severe bacterial sepsis with an all-cause mortality rate of 40.2%. The mortality rate for *Candida*sepsis was 46.4% with an attributable risk of 10/100 and was associated with a worse score of systemic injury (SAPS II = 51.7 ± 15.0), comparing with a mortality rate of 35.7% and SAPS II = 38.8 ± 13.3 for bacterial sepsis. *Candida*sepsis was always accompanied by concurrent bacterial sepsis (2.8 ± 1.1 microorganisms/patient isolated from blood cultures). Identified were risk factors with great significance in addition to already known ones: *Candida*colonization (OR = 3.4), diabetes (OR = 3.2), number of antibiotics used (OR = 2.9), a nothing per os regimen (OR = 2.63), ICU length of stay (OR = 1.97), length of antibiotic use (OR = 1.74), pancreatitis (OR = 1.7), shock at admission (OR = 1.54), ventilator days/ICU stay ratio (days)(OR = 1.4), multiple resistant bacterial strains (OR = 1.5). Patients with gastrointestinal surgery were at risk for development of early fungal sepsis -- by the 10th day of admission -- compared with the other clinical cases -- by the 21st day of admission. The incidence rate of positive blood cultures for *Candida*in the group exposed to our scheme was calculated as 6.7% vs 18.5% in the control group.

Conclusion
==========

Based on our results, we accepted an algorithm for performing a preemptive therapy for which we observed clinical efficacy and which we considered indicated the following target groups of patients: with presence of clinical features of unresolving sepsis plus three defined risk factors (PPV \> 70%) in a patient with length of ICU stay \>20 days; lack of clinical improvement with combined antibiotic treatment against established bacterial strains; evidence of sepsis accompanied with multifocal *Candida*colonization of sterile body spaces. *Candida*colonization without risk factors requires continuous monitoring. The most important presumption to accept the preemptive strategy for a certain patient is to have a serious clinical conviction that there is an invasive fungal infection but it is still pending to be proved.
